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Summary Malignant pleural mesothelioma is a rare
malignant disease that in the majority of cases is as-
sociated with asbestos exposure. The incidence in Eu-
rope is about 20 per million inhabitants and it is in-
creasing worldwide. Initial symptoms are shortness of
breath, pleural effusion, cough, and chest pain. The
typical growth pattern is along the pleural surface;
however, infiltration of the lung and/or mediastinal
and chest wall structures can occur in a more ad-
vanced stage. Ultimately, distant metastases outside
the chest can result. Several histological subtypes of
pleural mesothelioma exist, which must be differenti-
ated from either benign diseases or metastases in the
pleural space by other tumor entities. This differen-
tial diagnosis can be very difficult and a large panel of
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immunohistochemical markers is required to estab-
lish the exact diagnosis. The standard procedure for
confirming the disease and obtaining sufficient tis-
sue for the diagnosis is videothoracoscopy. Full thick-
ness biopsies are required, while transthoracic needle
puncture of pleural fluid or tissue is considered to be
insufficient for a cytological diagnosis. Complete and
detailed staging is mandatory for categorization of the
disease as well as for therapeutic decision making.
Keywords Malignant pleural mesothelioma · Epi-
demiology · Staging · Pathology · Diagnosis
J. Eckmayr
Department of Pulmonology, Landeskrankenhaus Wels,
Wels, Austria
Prim. Dr. C. Geltner, MSc, MBA · T. Klikovits · M. A. Hoda ·
W. Klepetko
Division of Thoracic Surgery, Department of Surgery,
Comprehensive Cancer Center, Medical University Vienna,
Währinger Gürtel 18–20, 1090 Vienna, Austria
H. Popper
Department of Pathology, Medical University Graz, Graz,
Austria
Austrian Mesothelioma Interest Group (AMIG)
Division of Thoracic Surgery, Department of Surgery,
Comprehensive Cancer Center, Medical University Vienna,
Waehringer Guertel 18–20, 1090 Vienna, Austria
K Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging 611
consensus report
Epidemiology
Asbestos exposure is the main risk factor for the devel-
opment of malignant pleural mesothelioma (MPM)
[1]. Asbestos comprises silicate minerals with very
thin fibers: chrysotile, crocidolite as serpentines,
amosite, anthophyllite, tremolite, and actinolite from
the amphibole group [2]. Chrysotile is biologically
active and detectable in the lungs for a shorter time.
Chrysotile, amosite, and crocidolite were mined and
used in ship and railway construction as well as in
fire protection engineering. The first evidence of
their high carcinogenic potential was found in the UK
and South Africa as early as the 1960s [3]. Amosite
and crocidolite seem to have a higher carcinogenicity
than the other types of asbestos [2]. Asbestos expo-
sure is typically labor-dependent and is recognized
as an occupational disease. More recently, a shift
has been observed from asbestos-removal workers
to professionals involved in post-construction work,
e. g., electricians, plumbers, or heat protection tech-
nicians. This is paralleled by a profession-dependent
gender distribution, as more than 80% of affected
individuals are men [4].
“Environmental” occurrence of mesothelioma has
been found in people growing up in the vicinity of
natural asbestos resources (Turkey, Corsica, Cyprus)
or in areas where asbestos was used for the whitening
of house walls. The load in rooms built with asbestos-
containing materials was initially seen as hazardous.
The actual resulting asbestos dose is, however, ex-
tremely low and carcinogenic levels are not detectable
[5].









































Furthermore, there is an increasing incidence of
nonoccupational asbestos disease among housewives
and family members of asbestos workers as well as
a high environmental impact in the vicinity of mining
and processing facilities [6, 7].
There is a clear correlation between the amount
of asbestos exposure and the incidence of MPM. The
mean latency period between exposure to asbestos
and the onset of symptoms is up to 40 years, and 99%
of cases show a latency of more than 15 years [8].
The occurrence of MPM is independent of other
asbestos-associated diseases such as classic asbesto-
sis of the lung (interstitial lung disease with fibrosis)
and benign pleural plaques. Although pleural plaques
are also associated with asbestos exposure, studies
from Australia could not find any connection between
plaques and an increased incidence of MPM [9].
The incidence of MPM varies between 7 per million
inhabitants in Japan and 40 per million in Australia.
In Europe, the average incidence is 20 per million in-
habitants. The frequency is highly dependent on the
amount of asbestos removal, asbestos import, and in-
dustrialization. In Europe, peak incidence is to be ex-
pected between 2015 and 2020 due to the long latency
period [10].
By contrast, the incidence of mesothelioma with-
out asbestos contact is extremely low (<1: 1 million).
Other potential cofactors for the development of
mesothelioma besides asbestos are synthetic materi-
als (ceramics, nanoparticles), ionizing radiation, and
SV-40 virus infections [11].
The impact of cigarette smoke as well as numerous
other fibrous materials such as glass fibers and min-
eral glass wool is, however, excluded. Genetic factors
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may play a role, since both familial clustering and en-
demic accumulation in populations with high natural
exposure are known in Turkey [5, 12].
In Austria, there have been 276 cases of MPM ap-
proved by the AUVA (Allgemeine Unfallversicherungs-
anstalt – General accident insurance company) as be-
ing caused occupationally within the last 5 years. Of
these, 53 were approved in 2014 only. In contrast
to this, ten asbestos-related MPM cases were docu-
mented in 1995 and 41 in 2005. However, there is
still uncertainty about the number of MPM cases not
being reported to the AUVA. A comparison of the in-
cidence of MPM worldwide and in Austria is depicted
in Fig. 1.
Screening
In the current European Society of Thoracic Surgery
(ESTS)/European Respiratory Society (ERS) guidelines









Fig. 3 Video-assisted tho-
racoscopic viewofMPM
mainlyon theparietal pleura
(a,b), forcepsbiopsy (c), and
talcpleurodesis (d)
no general screening methods are recommended
[13]. This is based on the low sensitivity of even
advanced imaging techniques such as low-dose com-
puted tomography (CT) in screening of asbestos work-
ers.
Circulating biomarkers, such as osteopontin, meso-
thelin-related peptides, and soluble mesothelin-re-
lated peptide (SMRP) [14], and fibulin-3 [15] have
also been evaluated in MPM extensively. However,
none of them are considered to be a reliable screen-




Specific symptoms of MPM are dyspnea, cough, and
chest pain on initial examination. Shortness of breath



























Fig. 4 Proposedstaging algorithm forMPMpatients inAustria
Table 1 Histological specificationofmalignantpleuralmesothelioma [23]





– Solid epithelioid patterns
– Small cell
– Oat cell
Differential diagnosis: metastatic carcinomas and
other epithelioid tumors
Mimic malignant mesenchymal tumors: leiomyosar-
coma synovial sarcoma
Desmoplastic mesothelioma bland tumor cells
Differential diagnosis: sarcomatoid carcinoma and
other sarcomas
Combination of all epithelioid and sarcomatoid
features
Differential diagnosis: Synovial sarcoma, other
mixed or biphasic tumors
Fig. 5 Examplesofmalignantpleuralmesothelioma (MPM): epithelioidMPMa), biphasicMPM (b), andsarcomatoidMPM(c).
(KindlyprovidedbyDr. LukaBrcic,DepartmentofPathology,MedicalUniversityGraz)
is often initially caused by a pleural effusion and later
by extensive restriction due to pleural and pulmonary
tumor masses in the thoracic cavity. Patients describe
chest pain as diffuse, sometimes radiating into the
shoulders, arms, or abdomen. Tumor ingrowth into
the neural structures of the brachial plexus and the
intercostal or paravertebral structures can also cause
neuropathic pain. Weight loss is a symptom of more
advanced disease.
Typically, MPM occurs initially unilaterally. The tu-
mor can, however, spread to the other pleural cavity or
into the peritoneum in the further course of disease.
Compared with lung cancer, distant metastases in the
extrathoracic lymph nodes or in other parenchymal
organs are usually rare, although they do occur in very
advanced stages [17].
Diagnostic procedures
The typical finding on chest X-rays of patients with
MPM is pleural effusion or pleural thickening, which,
however, is not specific. CT scan (Fig. 2) is more help-
ful, but it still does not allow a definitive diagnosis to
be made since its sensitivity reaches only 40%, and in
most cases it does not distinguish between benign and
malignant processes. The same holds true for positron
emission tomography (PET)-CT where no clear stan-
dardized uptake value (SUV) level is considered sug-
gestive for MPM and false-positive results can occur in
other processes such as tuberculosis, parapneumonic
effusions, and uremia [18].
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pleural tumor apical right
(top left), involving the vis-
ceral andparietal pleura in
thepleura costodiaphrag-
matic area (bottom leftand
right) and thepericardium
(top right)
Table 2 Clinical approachandpretherapeutic evaluation
according toERS/ESTS recommendations [13]
Investigation at presentation (all patients)
Demographics Gender, age, asbestos exposure
Clinical history Performance status symptoms
Physical examination Body weight
Radiology Chest radiograph
Blood tests –
Investigations for diagnosis and staging





Radiology – CT scan
– Brain MRI or CT
– Bone scan as required
Pulmonary function tests –
CT computer tomography, MRI magnetic resonance imaging
Puncture of the pleural effusion that is usually
present and cytological examination of the fluid is
also not conclusive, especially since the differential
diagnosis with pleural metastases of other tumors
such as bronchial or breast cancer (e. g., adenocar-
cinomas) cannot be made in most cases. Also the
macroscopic aspect of MPM is so variable that simple
thoracoscopy does not confirm the diagnosis.
For these reasons, the precise diagnosis of MPM
requires a histopathological confirmation and thora-
coscopy remains the standard procedure for obtain-
ing tissue and performing macroscopic staging of the
pleural tumor spread at the same time (Fig. 3). Tho-
racoscopy can be performed with the patient under
local anesthesia or as video thoracoscopy via a sur-
gical approach. This allows one to combine the di-
agnostic procedure with the initial therapeutic step of
talc pleurodesis (Fig. 3). Only in exceptional situations
should a CT- or ultrasound-guided fine needle biopsy
be performed, which, however, has a a clearly lower
sensitivity.
The typical diagnostic algorithm applied in most
centers around the world is displayed in Fig. 4.
Histopathology
MPM derives from the pleural stem cell, which ex-
hibits epithelioid and sarcomatoid growing patterns
at the same time. Depending on which component
is predominant, three histological types of MPM can
be distinguished: epithelioid (50–70%), sarcomatoid
(7–20%), and a mixed or biphasic form (20–35%; Ta-
ble 1 and Fig. 5).
The pathological diagnosis and differential diagno-
sis of MPM can be very challenging. In a French study,
the initial diagnosis of MPM was revised as false pos-
itive in 13% of cases [19]. This can be explained in
part by the fact that MPM can present in very het-
erogeneous forms on the one hand and must be dis-
tinguished from benign processes and other tumors,
especially metastases of various tumor entities, on the
other hand. Such a differential diagnosis can be par-
ticularly difficult sincemesothelioma-like features can
also be found in some lymphomas, thymomas, and
carcinomas, etc.
Full-thickness biopsies are required to separate in-
vasive from noninvasive growth patterns and a panel
of numerous immunohistochemical markers is re-
quired for the differentiation of epithelioid MPM
from adenocarcinoma [13].
Staging
Both CT and PET-CT (Fig. 6), however, are useful for
the further staging.
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Table 3 TNMstagingofmalignantpleuralmesothelioma [24]
T0 No evidence of primary tumor
T1 Tumor limited to the ipsilateral parietal pleura with or without mediastinal pleura and with or without diaphragmatic pleural involvement
T1a No involvement of the visceral pleura
T1b Tumor also involving the visceral pleura
T2 Tumor involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least one of the following:
– Involvement of the diaphragmatic muscle
– Extension of tumor from the visceral pleura into the underlying pulmonary parenchyma
T3 Locally advanced but potentially resectable tumor; tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and
visceral pleura) with at least one of the following:
– Involvement of the endothoracic fascia
– Extension into the mediastinal fat
– Solitary, completely resectable focus of tumor extending into the soft tissue of the chest wall
– Nontransmural involvement of the pericardium
T4 Locally advanced, technically unresectable tumor; tumor involving all of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and vis-
ceral pleura) with at least one of the following:
– Diffuse extension or multifocal masses of tumor in the chest wall, with or without associated rib destruction
– Direct diaphragmatic extension of the tumor to the peritoneum
– Direct extension of the tumor to the contralateral pleura
– Direct extension of the tumor to a mediastinal organ
– Direct extension of the tumor into the spine
– Tumor extending through to the internal surface of the pericardium with or without a pericardial effusion or tumor involving the myocardium
Regional lymph nodes (N)
NX Regional lymph node(s) cannot be assessed
N0 No regional lymph node metastases
N1 Metastases in the ipsilateral bronchopulmonary or hilar lymph node
N2 Metastases in the subcarinal or in the ipsilateral mediastinal lymph node, including the ipsilateral internal mammary and peridiaphragmatic nodes
N3 Metastases in the contralateral mediastinal, contralateral internal mammary, ipsilateral, or contralateral supraclavicular lymph nodes
Distant metastases (M)
M0 No distant metastasis
M1 Distant metastasis
Table 4 UICC–IMIGstaging [24]
UICC staging (7th edition)
Stage IA T1a N0 M0
Stage IB T1b N0 M0
Stage II T2 N0 M0


















For all patients, the following assessments for stag-
ing and further treatment are required: After initial
imaging with CT scan and confirmation of disease
via video-assisted thoracic surgery (VATS), a poten-
tial candidate for surgical treatment should undergo
PET-CT scanning to rule out distant metastasis and in-
volvement of the abdomen and the mediastinal lymph
nodes. To rule out the latter, histological confirma-
tion has to be made either by endobronchial/endo-
esophageal ultrasonography and transbronchial nee-
dle aspiration (EBUS/EUS-TBNA) or mediastinoscopy
or VATS according to the lymph node station involve-
ment and the involved side.
If nodes are negative, patients can proceed to in-
duction treatment and should be re-staged with CT
or PET-CT. In some cases of unclear involvement of
adjacent structures (e. g., chest wall), magnetic reso-
nance imaging (MRI) can be added in order to judge
the resectability.
The investigations shown in Table 2 were recom-
mended by many consensus groups.
The most recent available and widely used TNM-
based stating system was developed by the Interna-
tional Mesothelioma Interest Group (IMIG) and was
also approved by the Union for International Cancer
Control (UICC; Tables 3 and 4).
A possible staging algorithm for MPM patients is
displayed in Fig. 4.
Prognosis
The prognosis for MPM depends on the patient’s
age, gender, tumor stage, and geographic region [20].
Other factors such as weight loss and performance
status are important for the prognosis as in other
tumor entities as well as quality of life and symp-
tom scores. Epithelioid MPM has a better overall
prognosis than non-epithelioid histological subtypes.
Low hemoglobin levels, high platelet levels, and high
serum lactat dehydrogenase (LDH) are prognostically
unfavorable characteristics [21]. Numerous new lab-
oratory markers are in evaluation, but no validated
data on their prognostic value are available yet [22].
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